Is Lupin a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lupin Ltd is a average quality company .

Is Lupin undervalued or overvalued?

The key valuation ratios of Lupin Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Lupin share price return in the past 10 years?

Lupin Ltd share price has appreciated 3.4% annually (CAGR) over the past ten years.

Is Lupin a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Lupin Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Lupin Ltd - Stock Valuation and Financial Performance

Name: Lupin
Brand: Lupin

BSE: 500257 | NSE: LUPIN | Pharmaceuticals & Drugs | Mid Cap

Place order

Lupin Share Price

₹2,037.10 0.05 0.00%
as on 21-Nov'24 14:09

10 Year X-Ray of Lupin:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	40.3%	24.4%	18.6%	3.6%	8%	5.5%	9.7%	-7.1%	6.1%	16.2%	-
Value Creation Index ⓘ	2.6	1.2	0.7	-0.7	-0.3	-0.5	-0.1	-1.6	-0.5	0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	12,770	14,139	17,494	15,804	14,665	15,375	15,163	16,405	16,642	20,011	20,986
Sales YoY Gr.	-	10.7%	23.7%	-9.7%	-7.2%	4.8%	-1.4%	8.2%	1.4%	20.3%	-
Adj EPS ⓘ	53.2	49.2	57.9	5.1	8.8	-11.7	28.2	-34.6	7.9	42.1	57.6
YoY Gr.	-	-7.6%	17.7%	-91.2%	71.2%	-234.1%	NA	-222.8%	NA	429.9%	-
BVPS (₹) ⓘ	196.2	245.2	295	295.6	298.9	272	300.1	263.8	270.7	311.1	342.9
Adj Net Profit ⓘ	2,392	2,217	2,615	231	396	-531	1,280	-1,574	361	1,914	2,626
Cash Flow from Ops. ⓘ	2,733	-382	4,114	1,751	1,666	1,469	1,822	367	1,897	3,648	-
Debt/CF from Ops. ⓘ	0.2	-18.8	1.9	4.1	5.1	4.3	2.6	10.5	2.2	0.7	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.1%	6.4%	9.7%	20.3%
Adj EPS ⓘ	-2.6%	36.9%	14.3%	429.9%
BVPSⓘ	5.3%	0.8%	1.2%	14.9%
Share Price	3.4%	21.5%	31.3%	66.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	30.3	22.1	21.2	1.7	2.9	-4	9.7	-12.1	2.9	14.3	17.6
Op. Profit Mgn % ⓘ	29.4	26.3	26.2	19.9	17.5	15.3	17.5	1.3	10.3	19	22
Net Profit Mgn % ⓘ	19.1	15.7	15	1.5	2.8	-3.5	8.5	-9.5	2.3	9.7	12.5
Debt to Equity ⓘ	0.1	0.7	0.6	0.5	0.6	0.5	0.4	0.3	0.3	0.2	0
Working Cap Days ⓘ	163	205	209	141	153	136	138	132	145	133	123
Cash Conv. Cycle ⓘ	74	103	103	44	55	43	50	54	52	42	52

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 17.60%

Net Profit is growing at healthy rate in last 3 years 14.26%

Sales growth is good in last 4 quarters at 15.07%

Sales growth has been subdued in last 3 years 9.69%

Latest Financials - Lupin Ltd.

	Standalone	Consolidated
TTM EPS (₹)	65.7	57.6
TTM Sales (₹ Cr.)	15,347	20,986
BVPS (₹.) ⓘ	481.8	342.9
Reserves (₹ Cr.) ⓘ	21,887	15,551
P/BV ⓘ	4.23	5.94
PE ⓘ	31.00	35.38

From the Market
52 Week Low / High (₹)	1184.00 / 2312.00
All Time Low / High (₹)	0.80 / 2312.00
Market Cap (₹ Cr.)	92,930
Equity (₹ Cr.)	91.2
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Lupin:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Lupin

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Lupin

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	12,770	14,139	17,494	15,804	14,665	15,375	15,163	16,405	16,642	20,011
Operating Expenses ⓘ	9,150	10,454	13,001	12,657	12,104	13,020	12,596	16,190	14,921	16,222
Manufacturing Costs	1,683	2,147	2,648	2,521	2,174	2,295	2,360	2,632	2,656	3,231
Material Costs	3,806	3,894	4,661	4,734	4,437	4,963	4,854	5,781	6,024	5,645
Employee Cost	1,747	2,142	2,850	2,865	2,770	2,987	2,826	2,989	3,087	3,495
Other Costs ⓘ	1,914	2,271	2,843	2,537	2,723	2,775	2,556	4,788	3,154	3,851
Operating Profit ⓘ	3,620	3,685	4,493	3,148	2,561	2,355	2,567	215	1,721	3,789
Operating Profit Margin (%)	28.3%	26.1%	25.7%	19.9%	17.5%	15.3%	16.9%	1.3%	10.3%	18.9%
Other Income ⓘ	240	185	107	150	333	484	136	214	151	142
Interest ⓘ	10	59	153	204	302	363	141	143	274	312
Depreciation ⓘ	435	487	912	1,086	846	970	887	1,659	881	1,197
Exceptional Items ⓘ	0	0	0	-1,464	-340	-752	0	0	0	0
Profit Before Tax ⓘ	3,415	3,329	3,543	547	1,409	757	1,676	-1,372	716	2,422
Tax ⓘ	970	1,059	979	288	888	1,157	449	137	269	487
Profit After Tax	2,444	2,270	2,565	258	521	-400	1,228	-1,509	448	1,936
PAT Margin (%)	19.1%	16.1%	14.7%	1.6%	3.6%	-2.6%	8.1%	-9.2%	2.7%	9.7%
Adjusted EPS (₹)	53.5	50.2	56.6	5.6	13.4	-6.0	26.8	-33.6	9.5	42.0
Dividend Payout Ratio (%)	14%	15%	13%	90%	37%	-101%	24%	-12%	42%	19%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	8,818	11,049	13,324	13,366	13,524	12,322	13,614	11,992	12,316	14,176
Share Capital ⓘ	90	90	90	90	91	91	91	91	91	91
Reserves ⓘ	8,728	10,959	13,234	13,275	13,433	12,231	13,523	11,901	12,225	14,085
Minority Interest	24	32	35	40	47	44	55	69	78	83
Debt	471	7,119	7,952	6,876	8,222	4,286	3,066	3,844	4,244	2,670
Long Term Debt	102	5,374	5,648	6,425	6,642	1,793	16	142	28	0
Short Term Debt	369	1,745	2,304	452	1,580	2,493	3,049	3,702	4,217	2,670
Trade Payables	1,956	1,989	2,589	2,575	2,498	2,412	2,014	2,283	2,532	2,958
Others Liabilities ⓘ	1,784	2,100	2,200	2,731	2,925	5,745	4,682	3,464	3,631	3,808
Total Liabilities ⓘ	13,054	22,289	26,100	25,589	27,215	24,810	23,430	21,651	22,800	23,695
Fixed Assets
Gross Block	6,645	9,212	12,395	13,860	15,732	14,161	14,727	15,990	18,077	19,665
Accumulated Depreciation	2,276	495	1,362	3,498	4,645	6,222	6,846	8,609	9,722	10,654
Net Fixed Assetsⓘ	4,368	8,717	11,033	10,362	11,087	7,938	7,881	7,382	8,355	9,011
CWIP ⓘ	552	2,702	2,133	2,598	1,640	940	1,066	1,146	1,238	773
Investmentsⓘ	1,658	16	2,136	262	2,295	2,374	2,455	900	517	1,075
Inventories	2,504	3,274	3,642	3,662	3,837	3,457	4,092	4,631	4,492	4,954
Trade Receivables	2,657	4,549	4,307	5,192	5,150	5,446	4,474	4,262	4,481	4,692
Cash Equivalents	481	822	698	1,408	987	2,454	1,742	1,098	1,293	1,203
Others Assetsⓘ	834	2,209	2,150	2,104	2,220	2,200	1,720	2,233	2,425	1,988
Total Assets ⓘ	13,054	22,289	26,100	25,589	27,215	24,810	23,430	21,651	22,800	23,695

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	2,733	-382	4,114	1,751	1,666	1,469	1,822	367	1,897	3,648
PBT ⓘ	3,415	3,329	3,543	547	1,517	877	1,676	-1,372	716	2,422
Adjustment ⓘ	357	585	1,215	2,782	1,588	1,574	1,033	1,708	1,097	1,467
Changes in Working Capital ⓘ	-95	-3126	505	-1019	-500	-471	-192	-15	327	86
Tax Paid ⓘ	-944	-1,170	-1,149	-558	-939	-511	-695	47	-243	-326
Cash Flow From Investing Activity ⓘ	-1,055	-6,962	-2,527	470	-3,282	1,107	-1,240	1,292	-1,287	-1,712
Capex	-868	-5,781	-2,601	-1,490	-960	-671	-671	-898	-1,461	-917
Net Investments	370	1	13	1,919	-2,427	56	-608	2,304	105	-842
Others ⓘ	-557	-1,182	60	41	104	1,722	40	-114	70	46
Cash Flow From Financing Activityⓘ	-197	5,836	433	-1,492	744	-891	-1,885	-1,572	-337	-2,184
Net Proceeds from Shares ⓘ	41	54	43	15	4	6	11	16	2	15
Net Proceeds from Borrowing ⓘ	-69	5,233	343	972	158	-989	-1,721	126	-113	-28
Interest Paid ⓘ	-11	-58	-151	-204	-280	-356	-152	-124	-227	-283
Dividend Paid ⓘ	-134	-337	-338	-338	-225	-226	-272	-295	-183	-183
Others ⓘ	-24	945	536	-1,937	1,088	675	249	-1,295	183	-1,706
Net Cash Flow ⓘ	1,482	-1,508	2,019	729	-872	1,685	-1,303	87	273	-248

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	31.09	22.85	21.05	1.94	3.88	-3.09	9.47	-11.79	3.68	14.61
ROCE (%)	40.3	24.42	18.57	3.56	7.97	5.45	9.71	-7.11	6.06	16.24
Asset Turnover Ratio	1.11	0.81	0.73	1.05	1	1.15	1.17	1.32	1.28	1.37
PAT to CFO Conversion(x)	1.12	-0.17	1.6	6.79	3.2	N/A	1.48	N/A	4.23	1.88
Working Capital Days
Receivable Days	73	92	92	64	71	65	64	54	56	53
Inventory Days	66	74	72	49	52	44	49	54	59	54
Payable Days	146	162	161	176	179	164	162	133	144	177

Lupin Ltd Stock News

Lupin Ltd FAQs

What is the share price of Lupin?

Company share prices are keep on changing according to the market conditions. The closing price of Lupin on 21-Nov-2024 14:09 is ₹2,037.1.

What is the market cap of Lupin?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 14:09 the market cap of Lupin stood at ₹92,929.7.

What is the P/E ratio of Lupin?

The latest P/E ratio of Lupin as of 21-Nov-2024 14:09 is 31.00.

What is the P/B ratio of Lupin?

The latest P/B ratio of Lupin as of 21-Nov-2024 14:09 is 4.23.

What is the 52-week high and low of Lupin?

The 52-week high of Lupin is ₹2,312 and the 52-week low is ₹1,184.

What is the TTM revenue of Lupin?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lupin is ₹15,347 ( Cr.) .

About Lupin Ltd

Lupin was founded on the auspicious ‘Guddi padwa’ Day in 1968 by Dr. Desh Bandhu Gupta - a visionary with a compelling mission to create a better world for people. DBG as he was fondly called, started the company with a dream - a dream to fight life-threatening, infectious diseases with affordable and high-quality drugs of the highest social priority. With his vision, inimitable commitment and passion, Dr. Gupta steered the organization to become one of the fastest-growing Generic pharmaceutical companies around the world.The name ‘Lupin’ was inspired by the flower Lupin which is known to nourish the soil it grows in.

The Lupin flower is also known to be tolerant of the infertile soils and capable of pioneering change in barren and poor climates. This inspiration is at the core of the company’s ethos as it relentlessly strives to build medical solutions to meet the unmet needs of the society not just for a few but for the many across the globe.

Lupin is recognised as one of the world's largest manufacturers of Tuberculosis drugs. The company have significant market share across multiple therapy areas such as Cardiovascular (prils and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). To add to this, the company has proud to maintain over the years its global leadership positions in other therapy areas such as Anti-TB and Cephalosporin.

Business area of the company

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Products and services offered by the company

Global Formulations
Active Pharmaceuticals Ingredients (API)
Biotech
Specialty Business
Over The Counter (OTC)
Global Manufacturing & Supply Chain

Awards

2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.
2007: Amerisource Bergen, One Of The Largest And Leading Wholesalers In The US Conferred The ‘Best New Manufacturer Of The Year, Generics Rx’ To Lupin Pharmaceuticals Inc.
2008: ‘Walmart Supplier Award Of Excellence’ For Overall Commitment, Performance, On-Time Shipping, Innovative Programs And Overall Partnership.
2009: International Excellence Award by Institute Of Economic Studies.
2009: Outstanding Export Performance Award by Pharmexcil (Pharmaceuticals Export Promotion Council Of India).
2010: Indian Pharmaceutical Company Of The Year 2010 By Frost & Sullivan India Excellence In Healthcare Awards 2010.
2010: Best Drug Development Company, Asia by The New Economy Pharmaceutical & Healthcare Awards 2010.
2010: Lupin Wins 'The Most Promising Entrant Into The Big League' by CNBC India Business Leader Awards 2010.
2011: Healthcare Distribution Management Association (HDMA) Honors Lupin With DIANA Award For Best Overall Generic Product Manufacturer.
2011: Top Indian Pharma Company under The 'Pharmaceuticals' Sector For The Dun & Bradstreet Rolta Corporate Awards 2010.
2011: Lupin Ranked Amongst India's Top 3 'Best Companies To Work For' In Healthcare And Pharma Sector.
2011: Hall Of Fame Award By Chemtech Foundation (Leadership And Excellence Awards).
2011: IMM (Institute Of Marketing And Management) Award For Excellence As Top Organisation.
2011: Lupin Ranked 2nd Amongst India's ‘Best Companies To Work For’ In The Biotechnology And Pharmaceutical Sector.
2012: Lupin Bags ‘Niryat Shree’ Gold Trophy for ‘Outstanding Export Performance’ In The Category Of Chemicals, Drugs, Pharma And Allied Products, During The Year 2009-2010, By FIEO (Federation Of Indian Export Organisations).
2012: The Economic Times 500 ‘India’s 10 Most Resilient Companies 2012’
2012: Dr Desh Bandhu Gupta (Founder & Chairman) has won the ‘Ernst & Young Entrepreneur of the Year 2011’ Award In The Life Sciences And Healthcare Sector.
2012: Lupin Has Won The NDTV Business Leadership Awards, 2011: Indian Pharmaceutical Company Of The Year
2012: Mrs Vinita Gupta Won The Business Today ’30 Most Powerful Women In Business’ Award.
2012: Mr Ramesh Swaminathan Won The Business Today Yes Bank ‘Best CFO Award - Best Leverage Management - Large Companies’.
2013: Mr Ramesh Swaminathan Bags The CNBC ‘Best CFO’ Award For Pharmaceutical Sector 2012
2013: Dr Kamal Sharma Bags The Business Today Best CEO Awards 2013
2013: Dr Desh Bandhu Gupta (Founder And Chairman) Won The Frost & Sullivan - Lifetime Achievement Award
2013: Ms Vinita Gupta, CEO, Lupin Pharmaceuticals, Bagged The Ernst & Young US 2012 ‘Family Business Award’
2013: Ms Vinita Gupta, CEO, Lupin Pharmaceuticals, Bagged The Ernt & Young ‘Entrepreneur Of The Year 2012 Award’ In Maryland.
2014: Ms Vinita Gupta - Forbes Asia Businesswomen - Power 50
2015: Ms Vinita Gupta, CEO amongst the Most Powerful Business Women 2015 By Business Today.
2015: The Best CFO Award By FinanceAsia - Mr Ramesh Swaminathan.
2015: Lupin #1 In Pharma In ‘Best At Investor Relations’ By FinanceAsia; 5th In Overall Ranking.
2015: Risk Management Firm of The Year (Pharma) At CNBC TV18 India Risk Management Awards.
2015: ICAI (Institute Of Chartered Accountants Of India) Awards For Excellence In Financial Reporting For The Year 2013-14.
2015: ‘Outstanding Company Of The Year’ - CNBC-TV18 India Business Leadership Awards, 2014-15.
2016: ‘Entrepreneur Of The Year’ - Forbes India Leadership Awards 2016 – Ms Vinita Gupta, CEO And Mr Nilesh Gupta, MD
2016: Outstanding Company Of The Year By CNBC-TV18
2016: Outstanding Woman Business Leader Of The Year -CNBC India Business Leadership Awards - Ms Vinita Gupta, CEO
2016: Lupin In AON Best Employers India 2016
2016: Lupin In Forbes World’s Most Powerful Public Companies
2016: Golden Peacock Award for Excellence In Corporate Governance
2016: Lupin Ranked 15th in The Great Places To Work ‘Best Companies To Work For In Asia’
2016: Ernst & Young ‘Entrepreneur Of The Year Award’ - Ms Vinita Gupta, CEO and Mr Nilesh Gupta, MD.
2017: Lupin Ranked No.1 In The Biotech And Pharma, And No. 4 Amongst Large Organisations In The List Of Top 100 - Great Place To Work 2017.
2017: Business World - Best CFO Award.
2017: Forbes Global 2000, FY 2017.
2017: BEST Award from ATD.
2017: Cardinal Supply Chain Excellence Award For 2017.
2017: Vinita Gupta - Hall Of Fame - The Most Powerful Business Women 2017 By Business Today.
2017: Walmart Supplier Of The Year Award For 2017.
2017: Lupin Ranked No.1 in The Biotech And Pharma, And No. 4 Amongst Large Organisations In The List Of Top 100 Great Place To Work.
2017: Business World - Best CFO Award.
2017: Dun & Bradstreet Corporate Award.
2017: Thomson Reuters India Innovation Award For Research & Development.
2018: Vinita Gupta: Vogue And IBM Businesswoman Of The Year 2018.
2018: Vinita Gupta Selected Women Of Worth 2018 By Outlook Business.
2018: Vinita Gupta Listed In Top 50 Most Powerful Women In Business 2018 By Fortune India.
2018: Crystal Globe Recognition Award In Oct 2018, Second Time In A Row.
2018: Dr D B Gupta Inducted Into ‘Hall Of Fame’ - CNBC TV18 India Business Leader Awards 2018.
2018: Lupin Receives The Prestigious Annual ‘Innovator Award’ From BioNJ, New Jersey.
2018: India Pharma Bulk Drug Company Of The Year 2018 - Department Of Pharmaceuticals, Government Of India.
2018: ‘BEST Award 2018’ From ATD.
2019: India Pharma Innovation Of The Year Award 2019 - Department Of Pharmaceuticals, Govt. Of India.
2019: Silver Awards for Quality By Design From ASQ (American Society Of Quality).
2019: Silver Award for Lean Six Sigma Project from QCFI (Quality Circle Forum Of India).
2019: McKesson Supplier Of The Year Award For 2019 In US.
2019: Three Of its Manufacturing Sites (Ankleshwar, Mandideep And Tarapur) Are At Level 7 Of ISRS 8th Edition - The Highest Safety Rating To Be Achieved By A Pharmaceutical Organisation.
2019: Lupin Won First Prize In CII National Six Sigma Award For Operational Excellence In Manufacturing.
2019: Lupin Won 2nd Prize in CII Kaizen Competition Held at Chandigarh (Restorative Kaizen).
2020: Lupin’s Ankleshwar Facility Wins Gold Award From American Society For Quality.
2020: Par Excellence Award by The Quality Circle Forum Of India (QCFI).
2020: Indian Drug Manufacturers’ Association (IDMA) Corporate Citizen Award 2019 to Lupin Foundation.
2020: India Pharma Leader Award -India Pharma Leader Award.

Milestones

1968: Lupin commences business.
1972: Lupin Laboratories Pvt. Ltd. is incorporated.
1979: Commissions first formulations plant and an R&D center at Aurangabad.
1981: Commences the production of Ethambutol.
1987: The Cephalexin Plant at mandideep and 7 ADCA plants at Ankleshwar go on stream.
1988: The Lupin Human Welfare And Research Foundation (LHWRF) is founded By Dr. Desh Bandhu Gupta.
1989: Gets into a joint venture in Thailand and Lupin Chemicals (Thailand) is established receives US FDA approvals for Ankleshwar and Mandideep plants.
1991: Initiates production of injectable Cephalosporin (Bulk And Dosages) at Mandideep
1992: Establishes a Fermentation Plant Of Lupin Chemicals Tarapur, Maharashtra Commissions a sterile plant for injectable Cephalosporins (Bulk) at Mandideep.
1993: Lupin Laboratories and Lupin Chemicals raise money through IPOs.
1997: Receives USFDA approvals for three plants - Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur.
1998: Receives UK MCA approval for the injectable Cephalosporin Dosages plant at Mandideep.
1999: Receives UK MCA approval for the Injectable Cephalosporin Bulk active plant at Mandideep.
2000: Receives USFDA approval for the Cefotaxime facility at Mandideep.
2001: State-of-the-art R&D Centre, Lupin Research Park at Pune is commissioned.
2001: Commences supply of Cephalosporin Bulk actives to its alliance partners in the US
2001: Lupin Laboratories is amalgamated with Lupin Chemicals and Retitled to Lupin.
2001: Becomes the only Asian pharmaceutical company to receive US FDA approvals for its Sterile Cephalosporin Facility.
2001: A State-Of-The-Art US FDA approved Oral Cephalosporin Bulk Active plant is commissioned at Mandideep.
2002: Exports To The Advanced Markets Cross ` 1000 Million; Rising Trend Of Exports As A % Of Total Revenue Which Went Up 33% Year-Over-Year.
2002: Patent filings cross 100.
2002: First five ANDAs filed.
2002: Filed five ANDAs.
2002: New Anti-TB facility commissioned at Aurangabad.
2002: Rablet rated by ORG-Marg as the second best launch of FY 2002-03.
2003: Receives WHO approval for State-Of-The-Art formulation plant, Aurangabad.
2003: Successfully implements SAP ERP across the company to unify all business functions and processes.
2003: Introduced collaborative messaging and workflow solution on the intranet.
2003: Receives US FDA approval for the Oral Cephalosporin Plant at Mandideep.
2003: Lupin Pharmaceuticals Inc. USA, was formed for trading, marketing and developmental activities in the US.
2004: Commences its US brands business with the launch Of Suprax.
2005: Receives USFDA approval for new Lovastatin plant at Tarapur.
2005: Receives the USFDA approval for Goa.
2005: Launches its generics business in the US with four products.
2005: Implements maiden employees stock option plan.
2006: Receives The MHRA (UK) and WHO approval for Goa
2006: Maiden Bonus Shares issued in the ratio of 1:1
2006: Maiden issue of Foreign Currency Convertible Bonds (FCCB) aggregating $100 Million, listed on The Singapore Stock Exchange.
2007: Acquires Kyowa Pharmaceutical Industry Company Ltd., a leading generics company In Japan.
2007: Acquires Vadodara Based Rubamin Laboratories Ltd. (Rechristened To Novodigm Ltd.)
2007: Starts commercial production at the new finished dosage facility At Jammu.
2008: Sets up a Biotech facility at Pune.
2008: Expands its product basket in Japan-Kyowa and receives approvals for ten products from the Ministry Of Health & Labour Welfare, Japan.
2008: Acquires Hormosan Pharma GmbH in Germany.
2008: Acquires a stake in Generic Health Pty Ltd., Australia.
2008: Acquires a majority stake in pharma dynamics, South Africa.
2009: Acquires the US Rights for Antara.
2009: Acquires majority stake in MultiCare Pharmaceuticals Philippines Inc.
2010: Emerges the 5th Largest Generic Player in the US.
2011: Starts commercial production at the New Oral Solid Dosage facility at Pithampur.
2011: Acquires I’rom Pharmaceuticals in Japan.
2011: Enters into a joint development agreement with Medicis.
2011: Acquires Worldwide Rights for the goanna brand.
2012: Enters the NIFTY 50 index
2013: Expands its branded play with exclusive US Rights to Alinia for oral suspensions.
2014: Inks strategic joint venture agreement with Yoshindo Inc. in Japan.
2014: Acquires Laboratorios Grin S.A. De C.V., Mexico, Specialty Ophthalmic Company and with this enters the Latin American Market.
2014: Acquires Nanomi B.V., enters Complex Injectables Space
2015: The Center Of Excellence For Inhalation Research In Coral Springs, Florida is inaugurated.
2015: Acquires the specialty product portfolio of Temmler Pharma GmbH & Co. in Germany.
2015: Acquires Medquimica Industria Farmaceutica S.A. In Brazil.
2015: Completes the acquisition of Pharma Dynamics in South Africa.
2016: Commissions a new plant at Tottori, Japan.
2016: Bolsters the US Brands Portfolio with Methergine Oral Tablets.
2016: Acquires branded product portfolio from Shionogi & Co. Ltd. in Japan.
2016: Acquires Gavis Pharma in New Jersey.
2016: Inaugurates a new plant at Visakhapatnam.
2017: Acquires Symbiomix Therapeutics, LLC in New Jersey
2017: Forays into the OTC segment with pan india launch of Softovac
2017: Inaugurates a new plant at Sikkim
2018: Commissions injectables facility at Nagpur
2018: Files a new drug application for Etanercept Biosimilar in Japan
2019: Divestment of Kyowa Pharmaceutical Industry Co.